[Effect of pazufloxacin mesilate, a new quinolone antibacterial agent, for intravenous use on QT interval].
The potential for QT interval prolongation of pazufloxacin mesilate (PZFX mesilate), a new quinolone antibacterial agent for intravenous use, was investigated by in vitro and in vivo electrophysiology studies. Following results were obtained. In vitro electrophysiology study using guinea pig papillary muscles: PZFX mesilate (30-300 microM) had no effects on resting membrane potential (RMP), action potential amplitude (APA) and action potential duration (APD). Reference quinolones, sparfloxacin (3-30 microM) and moxifloxacin (10-100 microM), had no effects on RMP and APA, but significantly prolonged APD at more than 3 and 10 microM, respectively, while ciprofloxacin (10-100 microM) had no effect on each parameter. In vivo electrophysiology study using anesthetized dogs: PZFX mesilate had no effects on electrocardiograph parameter (PR interval, QRS interval, QT interval and QTc) after intravenous administration of 3-30 mg/kg. These results suggest that PZFX mesilate has low potential for QT interval prolongation.
Fukuda
Hitoshi
H
Research Laboratories, Toyama Chemical Co. Ltd., 2-4-1 Shimookui, Toyama 930-8508, Japan.
Morita
Yukie
Y
Shiotani
Norio
N
Mizuo
Midori
M
Komae
Norihisa
N
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004285:Dogs; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D024841:Fluoroquinolones / Q000008:administration & dosage / Q000009:adverse effects*; D006168:Guinea Pigs; D066298:In Vitro Techniques; D007275:Injections, Intravenous; D008133:Long QT Syndrome; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D010078:Oxazines / Q000008:administration & dosage / Q000009:adverse effects*; D010210:Papillary Muscles / Q000187:drug effects; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010078:Oxazines; D015363:Quinolones; C078052:pazufloxacin